{"entity":{"id":"psma-1007-f18","kind":"drug","name":"PSMA-1007 F-18","aka":["Prostalumin"],"tldr":"PSMA-1007 is a fluorine-18 PSMA PET tracer from ABX in Germany, widely used in Europe for prostate cancer staging because little of it reaches the bladder, and in a phase 3 trial registered by its maker.","summary":"PSMA-1007, developed at Heidelberg and manufactured by ABX advanced biochemical compounds in Radeberg, is a fluorine-18 PSMA ligand whose low urinary excretion improves views of the prostate bed and pelvic nodes. It is authorised in several European countries and Canada and used in many centres alongside gallium-68 PSMA-11 and piflufolastat; a phase 3 trial by ABX is registered on ClinicalTrials.gov. Health Canada's Drug Product Database lists PROSTALUMIN ((18F)PSMA-1007, 3.7 GBq/mL intravenous solution, DIN 02571757) from the Centre for Probe Development and Commercialization in Hamilton, Ontario, with status Approved and a product monograph dated 24 September 2026.","status":"phase-3","asOf":"2026-10-04","links":[{"label":"ClinicalTrials.gov: trials of PSMA-1007 F-18","url":"https://clinicaltrials.gov/search?intr=PSMA-1007%20F-18"},{"label":"Health Canada Drug Product Database: PROSTALUMIN, DIN 02571757","url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=107378"}],"tags":["pipeline","ctgov-ingest"],"related":["f-18","ga-68"],"indications":["prostate"],"sections":[],"technologies":["psma-pet","pet"],"targets":["psma"],"drugs":[],"companies":["abx-advanced-biochemical-compounds"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06122584"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"Nuclide ingestion (ClinicalTrials.gov v2, curated)","editedOn":"2026-09-16"},"modality":"PSMA-targeted PET radiotracer, fluorine-18","mechanism":"A fluorine-18 PSMA ligand excreted mainly through the liver rather than the kidneys, so the bladder does not obscure the prostate bed on PET.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/psma-1007-f18/","neighbours":{"isotope":[{"id":"f-18","kind":"isotope","name":"Fluorine-18","route":"/isotopes/f-18/"},{"id":"ga-68","kind":"isotope","name":"Gallium-68","route":"/isotopes/ga-68/"}],"indication":[{"id":"prostate","kind":"indication","name":"Prostate cancer","route":"/indications/prostate/"}],"technology":[{"id":"pet","kind":"technology","name":"PET (positron emission tomography)","route":"/technologies/pet/"},{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/"}],"target":[{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/"}],"company":[{"id":"abx-advanced-biochemical-compounds","kind":"company","name":"ABX advanced biochemical compounds","route":"/companies/abx-advanced-biochemical-compounds/"}],"trial":[{"id":"nct06122584","kind":"trial","name":"Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer","route":"/trials/nct06122584/"}],"section":[{"id":"f-molecular-imaging","kind":"section","name":"Molecular imaging","route":"/fronts/f-molecular-imaging/"}]}}